MSLN has been regarded as an attractive target for CAR-T cell therapy because of abundant expression in tumor cells and limited expression in normal cells.16 In our previous study, the mesoCAR T cells exhibited rapid and robust killing effects on high MSLN-expressing metastatic ascites-derived pancreatic cancer-1 (ASPC-1) cells and restrained tumor growth in the ASPC-1 xenograft mice model with increased production of IFN-γ.15 mesoCAR T cells can effectively inhibit the growth of ovarian tumors in vivo mouse model.6 The gene discussed is IFNG; the disease is ovarian neoplasm.